ClinicalTrials.gg
RecruitingNCT07429461Updated Feb 24, 2026

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

An Early Phase 1 interventional study of SYNCAR-100 Injection in B-Cell Acute Lymphoblastic Leukemia, sponsored by Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Zhejiang University · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Burkitt Lymphoma with a site in China — 58 open to participants now, 62 under way, 4 of them phase 3. Burkitt Lymphoma · China.

Planned enrollment
76th of 100
16 · median 24
Started
2026
with 10 others
Phase 1
53 of 102
29 open now
Primary completion
2027-12
later than 39 of 61 live
Registered
93rd of 102
by date
Lead sponsor
6 of 102
Zhejiang University

Among the 102 studies in Burkitt Lymphoma with a site in China, this one is the 76th largest by planned enrollment of the 100 interventional ones that give a count, is one of 11 that started in 2026, is one of 53 in phase 1, reaches primary completion later than 39 of the 61 other live ones, and was the 93rd registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

58 of the 102 studies in Burkitt Lymphoma with a site in China are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Burkitt Lymphoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Participants who have signed the informed consent form will undergo screening against the inclusion and exclusion criteria. Eligible participants will receive study drug administration once weekly for a total of four doses, followed by a 1-year safety and efficacy follow-up observation period. After the completion of the study, long-term follow-up may be required for participants to monitor their health and survival status until 15 years post-treatment, or until the occurrence of patient death, loss to follow-up, or withdrawal of consent.

Read the detailed description

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the clonal abnormal proliferation and accumulation of lymphoid precursor cells (B or T lineage) in the bone marrow, peripheral blood and other organs. B-cell acute lymphoblastic leukemia (B-ALL) is the more common subtype, accounting for approximately 80% of all cases. For adult patients with relapsed or refractory B-ALL, only about 5-30% can achieve complete remission (CR) following salvage therapy. In addition, among patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), approximately 35% experience disease relapse, with a median overall survival of no more than 6 months; the estimated 1-year, 2-year and 5-year overall survival rates are about 30%, 15% and 10%, respectively. Relapse after allo-HSCT remains a major challenge in the treatment of hematologic malignancies, and there is no effective therapeutic approach recommended by clinical practice guidelines or consensus statements. Therapies such as retransplantation, donor lymphocyte infusion (DLI) and blinatumomab yield overall suboptimal efficacy, creating an urgent unmet medical need for novel and effective therapeutic strategies.

SYNCAR-100 is a next-generation nucleic acid drug candidate developed by Bisheng (Beijing) Biotechnology Co., Ltd. based on circular RNA (circRNA) technology. The safety of SYNCAR-100 will be evaluated by assessing indicators including dose-limiting toxicities (DLT), vital sign measurements, physical examinations, laboratory tests, 12-lead electrocardiography (ECG), peripheral blood B-cell and T-cell levels, and adverse events (AE). The efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) will be evaluated by measuring endpoints including the overall response rate (ORR) within 12 weeks, the rate of complete remission with minimal residual disease (MRD)-negativity, duration of response (DOR), progression-free survival (PFS), as well as the ORR within 48 weeks, the rate of patients achieving CR with MRD negativity, DOR, PFS and overall survival (OS). After the completion of the study, long-term follow-up may be required for participants to monitor their health and survival status until 15 years post-treatment, or until the occurrence of patient death, loss to follow-up, or withdrawal of informed consent.

03

Conditions studied

  • B-Cell Acute Lymphoblastic Leukemia

Keywords

  • B-Cell Acute Lymphoblastic Leukemia
  • Relapsed Refractory Leukemia
  • CD19 Antigens
  • Chimeric Antigen Receptor T-Cells
  • circRNA
  • Nucleic Acids
  • Drug Safety
  • Clinical Study
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Aged 18 to 75 years (inclusive), of any gender.
  • 2. Performance Status score ≥ 70.
  • 3.Estimated ≥ 12 weeks.
  • 4.Positive CD19 expression on tumor cells confirmed by flow cytometry in bone marrow or peripheral blood.
  • 5.Confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) by bone marrow examination, and meeting one of the following criteria:
  • ① B-ALL: Failure to achieve complete remission (CR) after 2 courses of standard induction chemotherapy, or failure to achieve CR after /multiline salvage chemotherapy.
  • ② Relapsed B-ALL: Relapse within 12 months after the first remission, or relapse after first-line/multiline salvage chemotherapy.
  • ③Relapse after or allogeneic hematopoietic stem cell transplantation (HSCT).
  • ④ For Philadelphia chromosome-positive (Ph+) patients: At least 2 lines of tyrosine kinase inhibitor (TKI) therapy have failed, or the patient is intolerant to TKI therapy, or the patient harbors the T315I mutation and is resistant to TKIs.
  • 6.Proportion of blasts and immature lymphocytes in bone marrow > 5% confirmed by bone marrow morphologic examination.
  • 7.No prior hematopoietic stem cell transplantation (HSCT) within 6 months before enrollment.
  • 8.Adequate organ function reserve, as defined by all of the following:
  • ① (calculated by the Cockcroft-Gault formula) > 60 mL/min: Male: Creatinine Clearance = [(140 - Age) × Body Weight (kg)] / [0.818 × Serum Creatinine (μmol/L)] Female: Creatinine Clearance = [(140 - Age) × Body Weight (kg) × 0.85] / [0.818 × Serum Creatinine (μmol/L)]
  • ② Serum (ALT) and aspartate aminotransferase (AST) \< 2.5 times the (ULN) ; for patients with hepatic , AST and ALT ≤ 5 times the upper limit of normal (ULN) .
  • ③Serum total \< 1.5 times the upper limit of normal (ULN) ; for patients with Gilbert's syndrome, total bilirubin ≤ 3 times the upper limit of normal (ULN) .
  • ④ Absolute lymphocyte count (ALC) ≥ 0.1 × 10\^9/L.
  • ⑤ (LVEF) > 50% confirmed by echocardiography, with no pericardial effusion on echocardiography.
  • ⑥ No clinically significant pleural effusion.
  • ⑦ Baseline peripheral oxygen saturation (measured at the fingertip) > 92% while breathing room air.
  • 9.For women of : Non-lactating; negative result of highly sensitive serum or urine pregnancy test during screening. All women of childbearing potential must use medically accepted methods (e.g., intrauterine device, oral contraceptives) throughout the treatment period and for 2 years after the first treatment. For males of childbearing potential: Sperm donation is prohibited during the same period.
  • 10.Ability to communicate effectively with investigators; willingness and ability to comply with the study protocol, complete all study-related procedures as required, and provide written (signed voluntarily by the patient or their legal guardian).

Exclusion criteria

Exclusion Criteria:

  • 1.Isolated extramedullary leukemia or isolated extramedullary relapse.
  • 2.Central nervous system (CNS) involvement of leukemia at CNS2 stage.
  • 3.A history of other malignant tumors, except for the following: cured non-melanoma skin cancer, carcinoma in situ of the uterine cervix, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, or other malignant tumors with disease-free survival for more than 5 years.
  • 4.Positive test results for any of the following infectious diseases: ; ; ; positive HBcAb with concurrent positive HBV DNA copy number; TPPA.
  • 5.Administration of live or attenuated within 4 weeks prior to enrollment.
  • 6.Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with tyrosine kinase inhibitor (TKI) therapy within 1 week prior to enrollment.
  • 7.Prior receipt of CD19-targeted therapy, CAR-T cell therapy, or other gene-edited T cell therapy.
  • 8.Grade ≥2 acute (GVHD) (per Glucksberg criteria) requiring treatment, or extensive chronic GVHD (per Seattle criteria) within 4 weeks prior to enrollment; or patients judged by the investigator to potentially require anti-GVHD therapy during the study period.
  • 9.Comorbidities judged by the investigator to require systemic therapy or other therapy during the study period; or receipt of allogeneic cellular therapy (e.g., donor lymphocyte infusion [DLI]) within 4 weeks prior to enrollment.
  • 10.Receipt of CNS-directed radiotherapy within 4 weeks prior to enrollment.
  • 11.Unresolved acute toxicities from prior therapy (excluding hematologic toxicities and alopecia) that have not recovered to Grade 1 or lower.
  • 12.Known life-threatening or other intolerance to the study drug, or a history of severe atopy.
  • 13.Active diseases (including but not limited to systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, etc.), excluding hypothyroidism that is controllable solely with hormone replacement therapy.
  • 14.Receipt of major surgery requiring general anesthesia within 4 weeks prior to enrollment; or failure to recover and achieve clinical stability from prior surgical treatment; or anticipated major surgery requiring general anesthesia during the study period.
  • 15.Use of other drugs within 28 days prior to enrollment.
  • 16.A history of any unstable cardiovascular disease within 6 months prior to enrollment, including but not limited to unstable angina pectoris, myocardial infarction, heart failure ( [NYHA] Class ≥III), severe cardiac arrhythmias requiring pharmacologic treatment; or receipt of percutaneous transluminal coronary angioplasty, coronary stenting, or coronary artery bypass grafting within 6 months prior to enrollment.
  • 17.A history of central nervous system (CNS) disease or disorders (e.g., seizure disorders, cerebral vascular ischemia/hemorrhage, dementia, cerebellar disease) or any autoimmune disease involving the CNS.
  • 18.Uncontrolled active infection at screening (e.g., sepsis, bacteremia, fungemia, viremia).
  • 19.Any other condition judged by the investigator to make the patient unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    SYNCAR-100 Treatment Group

    Weekly intravenous (IV) administration for 4 doses. The investigator and sponsor may determine the dosing interval and number of doses for subsequent dose cohorts based on the safety/tolerability, pharmacokinetic parameters, clinical efficacy and prior clinical study experience of the 0.02 mg/kg dose cohort.

    Drug: SYNCAR-100 Injection

Interventions

  • DrugSYNCAR-100 Injection

    Subjects will receive intravenous injections once weekly for a total of 4 injections.

06

What researchers measure

Primary outcomes

  1. Adverse events(AE)

    Evaluated through laboratory investigations, 12-lead electrocardiography, and vital signs.

    Time frame: within 48 weeks post-dose

Secondary outcomes

  1. Overall Response Rate(ORR)

    Assessed according to the remission criteria for acute lymphoblastic leukemia (ALL)

    Time frame: within 12 weeks and 48 weeks post-dose

  2. Minimal Residual Disease(MRD)

    Assessed according to the remission criteria for acute lymphoblastic leukemia (ALL)

    Time frame: within 12 weeks and 48 weeks post-dose

  3. Duration of Response(DOR)

    Assessed according to the remission criteria for acute lymphoblastic leukemia (ALL)

    Time frame: within 12 weeks and 48 weeks post-dose

  4. Progression-Free Survival(PFS)

    Assessed according to the remission criteria for acute lymphoblastic leukemia (ALL)

    Time frame: within 12 weeks and 48 weeks post-dose

  5. Overall Survival(OS)

    Assessed according to the remission criteria for acute lymphoblastic leukemia (ALL)

    Time frame: within 12 weeks and 48 weeks post-dose

  6. Pharmacokinetics(PK)

    Evaluated based on CAR copy number and other parameters in peripheral blood.

    Time frame: within 4 weeks post-dose

  7. Pharmacodynamics(PD)

    Peripheral blood cytokines within 48 weeks after SYNCAR-100 infusion.

    Time frame: within 48 weeks post-dose

  8. Anti-Drug Antibody(ADA)

    Anti-SYNCAR-100 antibodies (ADA) in peripheral blood within 48 weeks after SYNCAR-100 infusion.

    Time frame: within 48 weeks post-dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2027, 22 months later.

Of 87 non-industry phase 1 interventional studies under Burkitt Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 90. This study's planned 22 months is below that.

Counting every sponsor, half of 110 studies reached it within 61 months; a quarter within 38 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 24, 2026
StartEst.
Feb 28, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2041
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07429461
Collaborators
Bisheng (Beijing) Biotechnology Co., Ltd.
Responsible party
He Huang (Clinical Professor, Zhejiang University) — Principal investigator
First posted
Feb 24, 2026
Start date
Feb 28, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2041 (estimated)
Last update
Feb 24, 2026

Study contacts

He Huang, MD
Contact
hehuangyu@126.com
13605714822
Yongxian Hu, MD
Contact
huyongxian2000@aliyun.com
057187233772

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion